References
- 1. Orvig, C. & Abrams, M.J. (1999). Medicinal inorganic chemistry: introduction. Chem Rev. 99, 2201-2203.
- 2. Alderden, R.A., Hall, M.D., & Hambley, T.W. (2006). The Discovery and development of cis-platin. J Chem Edu. 83, 728-734.
- 3. Sadler, P.J., Li, H., & Sun, H. (1999). Coordination chemistry of metals in medicine: target sites for bismuth. Coord Chem Rev. 185-186, 689-709.
- 4. Kaim, W. & Schwederski, B. (1993). Bioinorganic chemistry: Inorganic element in the chemistry of life. Wiley: Stuttgart.
- 5. Rosenberg, B., Van Camp, L., & Krigas, T. (1965). Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 205, 698-699.
- 6. Rosenberg, B., Van Camp, L., Trosko, J.E., & Mansour, V.H. (1969). Platinum compounds - a new class of potent antitumour agents. Nature. 222, 385-386.
- 7. Burger, H., Loos, W.J., Eechoute, K., Verweij, J., Mathijssenm R.H.J, & Wiemer, E.A.C. (2011). Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Res Up. 14, 22-34.
- 8. Hartinger, C.G., Groessl, M., Meier, S.M., Casinif, A., & Dyson, P.J. (2013). Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. Chem Soc Rev. 42, 6186-6199.
- 8. Quiroga, A.G. (2012). Understanding trans platinum complexes as potential antitumor drugs beyond targeting DNA. J Inorg Biochem. 114, 106-112.
- 9. Chin, C.F., Wong, D.Y.Q., Jothibasu, R., & Ang, W.H. (2011). Anticancer Platinum (IV) prodrugs with novel modes of activity. Curr Top Med Chem. 11, 2602-2612.
- 10. Kauffman, G. (2010). Michele Peyrone (1813-1883), Discoverer of Cisplatin. Platinum Metals Rev. 54(4), 250-256.
- 11. Sabo, T., Sipka-Grujicic, S., & Trifunovic S. (2002). Transition metal complexes with edda-type ligands-a review. Synth React Inorg Met Org Chem. 32(9), 1661-1717.
- 12. Todd, R.C. & Lippard, S.J. (2009). Inhibition of transcription by platinum antitumor compounds. Metallomics. 1, 280-291.
- 13. Jung, Y.W., & Lippard, S.J. (2007). Direct cellular responses to platinuminduced DNA damage. Chem Rev. 107, 1387-1407.
- 14. Reedijk, J. (1999). Why Does Cisplatin Reach Guanine- N7 with Competing S-Donor Ligands Available in the Cell? Chem Rev. 99(9), 2499-2510.
- 15. Barry, N.P., & Sadler, P.J. (2013). Exploration of the medical periodic table: towards new targets. Chem Commun (Camb). 49, 5106-5131.
- 16. Muggia, F.M., & Fojo, T. (2004). Platinums: Extending Their Therapeutic Spectrum. J. Chemother. 16 (Suppl. 4), 77-82.
- 17. Kociba, R., Sleiht, S.D., & Rosenberg, B. (1970). Inhibition of Dunning ascitic leukemia and Walker 256 carcinosarcoma with cisdiamminedichloroplatinum (NSC-119875). Cancer Chemother Rep. 54, 325-328.
- 18. Weiss, R.B., & Christian, M.C. (1993). New cis-platin analogues in development: A review. Drugs. 46, 360-377.
- 19. Ali, I., Wani, W., Saleem, K., & Haque, A. (2013). Platinum Compounds: A Hope for Future Cancer Chemotherapy. Anticancer Agents Med Chem. 13, 296-306.
- 20. Kostova, I. (2006). Platinum Complexes as Anticancer Agents. Rec Pat Anti-Canc Drug Disc. 1, 1-22.
- 21. Hamilton, G., & Olszewski, U. (2013). Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer. Drug Evaluations. 9(10), 1381-1390.
- 22. Jakupec, M.A., Galanski, M., & Keppler, B.K. (2003). Tumor inhibiting platinum complexes- state of the art and future perspectives. Rev Physiol Biochem Pharmacol. 146, 1-53.
- 23. Armand, J.P., Bolgie, V., Raymond, E., Fizazi, K., Faivre, S., & Ducreux, M. (2000). Oxaliplatin in colorectal cancer: an overview. Semin Oncol., 27, 96-104.
- 24. Kelland, L. (2007). The Resurgence of Platinum-based Cancer Chemotherapy. Nat Rev Cancer. 7: 573-584.
- 25. Boulikas, T., & Vougiouka, M. (2003). Cis-platin and platinum drugs at the molecular level. Oncol. Rep. 10, 1663-1682.
- 26. Martindale. (2007) The complete drug reference,; 35th ed.; S.C. Sweetman, Ed.; Pharmaceutical Press: London.
- 27. Cassidy, J., & Misset, J.L. (2002). Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 29, 11-20.
- 28. Alberto, E.M., Lucas, M.F.A., Pavelka, M., & Russo, N. (2009). The secondgeneration anticancer drug nedaplatin: a theoretical investigation on the hydrolysis mechanism. J Phys Chem. B. 113, 14473-14479.
- 29. Van Meerten, E., Eskens, F.A., van Gameren, E.C., Doorn, L., & van der Gaast, A. (2007). First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer. 96, 1348-1352.
- 30. Gentzler, R.D., & Johnson, M.L. (2015).Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist. 20(3), 299-306.
- 31. Kelland, L. (2007). Broadening the clinical use of platinum drug-based chemotherapy with new analogues, Satraplatin and picoplatin. Expert Opin Investig Drugs. 16, 1009-1021.
- 32. Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7, 573-584.
- 33. Wilson, J.J., & Lippard, S.J. (2014). Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev. 114(8), 4470-4495.
- 34. Welink, J., Boven, E., Ver Morken, J.B., Gall, H.E., & Vijgh WJF. (1999). Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clin Cancer Res. 5, 2349-2358.
- 35. Hall, M.D., Mellor, H.R., Callaghan, R., & Hambley, T.W. (2007). Basis for design and development of platinum(IV) anticancer complexes. J Med Chem. 50(15), 3403-3411.
- 36. Fuertes, M.A., Alonso, C., & Pérez, J.M. (2003). Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 103, 645-662.
- 37. Galanski, M., Jakupec, M.A., & Keppler, B.K. (2005). Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Curr Med Chem. 12: 2075-2094.
- 38. Wheate, N.J, Walker, S., Craig, G.E., & Oun, R. (2010). The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39, 8113-8127.
- 39. Nafees, M., & Zijian, G. (2014). Metal-basd anticancer chemotherapeutic agents. Curr Opin Chem Biol. 19, 144-153.
- 40. Wexselblatt, E., & Gibson, D. (2012). What do we know about the reduction of Pt(IV) pro-drugs? J Inorg Biochem. 117, 220-229.
- 41. Horváth, V., Blanárová, O., Svihálková-Sindlerová, L., Soucek, K. Hofmanová, J., Sova, P., Kroutil, A., Fedorocko, P., & Kozubík, A. (2006). Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol. 102(1), 32-40.
- 42. Svihálková-Sindlerová, L., Foltinová, V., Vaculová, A., Horváth, V., Soucek, K., Sova, P., Hofmanová, J., & Kozubík, A. (2010). LA-12 overcomes confluence-dependent resistance of HT-29 colon cancer cells to Pt (II) compounds. Anticancer Res. 30(4),1183-1188.
- 43. Liu, C.H. (1964). Some Homo- and Heteropolynuclear Chelates. Inorg. Chem. 3 (5), 678-680.
- 44. Jolley, J.N., Yanovsky, A.I., Kelland, L.R., & Nolan, K.B. (2001), Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents. Crystal and molecular structure of [PtL4CL2].H20 where L4 is ethylenediamine-N, N’-diacetate. J Inorg Biochem. 83(2-3), 91-100.
- 45. Davies, S.M., Wong, P.N., Battle, A.R., Haddad, G., McKeage, M.J., & Hambley, T.B. (2002). Examination of the effects of oxidation and ring closure on the cytotoxicities of the platinum complexes of N-(2-hydroxyethyl) ethane-1,2-diamine and ethane-1,2-diamine-N,N′- diacetic acid. J Inorg Biochem. 91(1), 205-211.
- 46. Kaludjerovic, G., Schmidt, H., Schwieger, S., Wagner, C., Paschke, R., Dietrich, A., Mueller, T., & Steinborn., D. (2008). Platinum(IV) complexes with ethylenediamine- N, N’-diacetate diester (R2edda) ligands: Synthesis, characterization and in vitro antitumoral activity. Inorganica Chimica Acta 361, 1395-1404.
- 47. Kaludjerovic, G., Pantelic, N., Eichhorn, T., Bette, M., Wagner, C., Zmejkovski, B., & Schmidt., H. (2014). Platinum(II) complexes with R2edda ligands (R = Me, Et, n-Pr; edda = ethylenediamine-N, N’- diacetate):Synthesis and characterization. Polyhedron. 80, 53-59.
- 48. Sabo, T., Kaludjerovic, G., Poleti, D., Karanovic, Lj., Boccarelli, A., Cannito, F., & Natile, G. (2004). Cytotoxicity of some platinum(IV) complexes with ethylenediamine- N, N’-di-3-propionato ligand. J Inorg Biochem. 98, 1378-1384.
- 49. Kaludjerovic, G., Dinovic, V., Juranic, Z., Stanojkovic, T., & Sabo, T. (2005). Activity of some platinum(II/ IV) complexes with O,O-n-butyl-and O,O-n-pentylethylenediamine- N, N’-di-3-propanoate and halogeno ligands against HeLa and K562 cell lines and human PBMC. J Inorg Biochem. 99,488-496.
- 50. Kaludjerovic, G., Miljkovic, Dj., Momcilovic, M., Djinovic, V., Mostarica Stojkovic, M., Tibor, S., & Trajkovic, V. (2005). Novel platinum(IV) complexes induce rapid tumor cell death in vitro. Int J Cancer. 116, 479-486.
- 51. Kaluaerovic, G., Kommera, H., Schwieger, S., Paethanom, A., Kunze, M., Schmidt, H., Paschke, R., & Steinborna, D. (2009). Synthesis, characterization, in vitro antitumoral investigations and interaction with plasmid pBR322 DNA of R2eddp-platinum(IV) complexes (R = Et, n-Pr) Dalton Trans. 28(48), 10720-10726.
- 52. Maksimovic-Ivanic, D., Mijatovic, S., Mirkov, I., Stosic- Grujicic, S., Miljkovic, Dj., Sabo, T., Trajkovic, V., & Kaludjerovic, G. (2012). Melanoma tumor inhibition by tetrachlorido(O,O’-dibutylethylenediamine-N, N’- di-3 propionate)platinum(IV) complex: in vitro and in vivo investigations. Metallomics, 4, 1155-1159.
- 53. Krajcinocic, B., Kaludjerovic, G., Steinborn, D., Scmidt, H., Wagner, C., Zizak, Z., Juranic, Z.D., Trifunovic, S.R., & Sabo, T.J. (2008). Synthesis and iv vitro antitumoral activity of novel O,O’-di-2-alkyl-(S,S)-ethylenediamine- N-N’-di-2-propanoate ligands and corresponding platinum(II/IV) complexes. J Inorg Biochem. 102, 892-900.
- 54. Djinovic, V., Glodjovic, V., Vasic, G., Trajkovic, V., Klisuric, O., Stankovic, S., Sabo, T., & Trifunovic, S. (2010). Synthesis, characterization and cytotoxicity of novel platinum(IV) complexes with ethylenediamine- N,N0-di-S,S-2-propanoate and halogenido ligands: Crystal structure of s-cis-[Pt(S,S-eddp)Cl2]*4H2O and uns-cis-[Pt(S,S-eddp)Br2]. Polyhedron. 29, 1933-1938.
- 55. Stojkovic, D., Jevtic, V., Radic, G., Dacic, D., Curcic, M., Markovic, S., Djinovic, V.M., Petrovic, V., & Trifunovic, S. (2014). Synthesis, characterization and in vitro antiproliferative activity of platinum(IV) complexes with some O,O’-dialkyl esters of (S,S)-ethylenediamine-N, N’- di-2-propanoic acid against colon cancer (HCT-116) and breast cancer (MDA-MB-231) cell lines. J Mol Struct. 1062, 21-28.
- 56. Kaludjerovic, G., Mijatovic, S., Zmejkovski, B., Bulatovic, M., Gomez-Ruiz, S., Mojic, M., Steinborn, D., Miljkovic, D.M., Schmidt, H., Stosic-Grujicic, S.D., & Sabo, T.J. (2012). Platinum(II/IV) complexes containing ethylenediamine-N, N’-di-2/3- propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells .Metallomics. 4, 979-987.
- 57. Volarevic, V., Vujic, J.M., Milovanovic, M., Kanjevac, T., Volarevic, A., Trifunovic, S., & Arsenijevic, N. (2013). Cytotoxic effects of palladium(II) and platinum(II) complexes with O,O’-dialkyl esters of (S,S)-ethylenediamine- N, N’-di-2-(4-methyl) pentanoic acid on human colon cancer cell lines. J BUON. 18(1), 131-137.
- 58. Lazic, J.M., Vucicevic, L., Grguric-Sipka, S., Janjetovic, K., Kaluderovic, G.N., Misirkic, M., Gruden-Pavlovic, M., Popadic, D., Paschke, R., Trajkovic, V., & Sabo, T.J. (2010). Synthesis and in vitro anticancer activity of octahedral platinum(IV) complexes with cyclohexylfunctionalized ethylenediamine-N, N’-diacetate- type ligands. Chem Med Chem. 5, 881-889.
- 59. Vujic, J., Kaludjerovic, G., Milovanovic, M., Zmejkovski, B., Volarevic, V., Zivic, D., Djurdjevic, P., Arsenijevic, N., & Trifunovic, S.R. (2011). Synthesis, characterization and in vitro antitumoral activity of platinum(II) complexes with O,O’-dialkyl esters of (S,S)-ethylenediamine- N, N’-di-2-(4-methyl)pentanoic acid. Eur J Med Chem. 46, 4559-4565.
- 60. Vujic, J., Kaludjerovic, G., Zmejkovski, B., Milovanovic, M., Volarevic, V., Arsenijevic, N., Stanojkovic, T., & Trifunovic, S. (2012). Synthesis, characterization and in vitro antitumoral activity of platinum(IV) complexes with O,O’-dialkyl-( S,S)-ethylenediamine-N, N’-di-2-(4-methyl)pentanoate ligands. Inorganica Chimica Acta. 390, 123-128.
- 61. Miljkovic, Dj., Poljarevic, J., Petkovic, F., Blazevski, J., Momcilovic, M., Nikolic, I., Saksida, T., Stosic-Grujicic, S., Grguric- Sipka, S., & Sabo, T.J. (2012). Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N, N’-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects. Eur J Med Chem. 47, 194-201.
- 62. Mihajlovic, Lj., Savic, A., Poljarevic, J., Vuckovic, I., Mojic, M., Bulatovic, M., Maksimovic-Ivanic, D., Mijatovic, S., Kaludjerovic, G.N., Stosic-Grujicic, S., Miljkovic, Dj., Grguric-Sipka, S, & Sabo, T.J. (2012). Novel methylene modified cyclohexyl ethylenediamine-N,N′-diacetate ligands and their platinum(IV) complexes. Influence on biological activity. J Inorg Biochem. 109, 40-48.
- 63. Mihajlovic, Lj., Stankovic, D., Poljarevic, J., Manojlovic, D., Sabo, T., & Grguric-Šipka, S. (2013). Electrochemistry and Bioactivity Relationship of Pt(IV) Complexes with Cyclohexyl-Functionalized Ethylenediamine-N, N’-Diacetate-Type Ligands. Int J Electrochem Sci. 8, 8433 - 8441.
- 64. Savic, A., Filipovic, L., Arandjelovic, S., Dojcinovic, B., Radulovic, S., Sabo, T., & Grguric-Sipka, S. (2014). Synthesis, characterization and cytotoxic activity of novel platinum(II) iodido complexes. Eur J Med Chem. 82, 372-384.
- 65. Dimitrijevic, D., Glodjovic, V., Radic, G., Garcia- Granda, S., Menendez-Taboada, L., Milovanovic, M., Volarevic, V., Arsenijevic, N., Bogdanovic, G., & Trifunovic, S. (2013). Synthesis, characterization and cytotoxicity of novel platinum(IV) complexes with some esters of ethylenediamine-N, N’-di-S,S-(2,2’-dibenzyl) acetic acid. Crystal structure of O,O’-dipropyl-ethylenediamine- N, N’-di-S,S-(2,2’-dibenzyl)acetate dihydrochloride. Inorganica Chimica Acta 402, 83-89.